Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 6/20 | 0.41 |
| ▸ | PPP5C | P53041 | 2/20 | 0.41 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | PPP1CC | P36873 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.37 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.37 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20215684 | 0.89 | PPM1B (0.48) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377988 | 0.88 | TFPI2 (0.43) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL20215685 | 0.88 | TFPI2 (0.43) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377959 | 0.85 | TFPI2 (0.40) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377916 | 0.85 | PPM1B (0.55) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26378031 | 0.81 | PPM1B (0.60) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377945 | 0.78 | TFPI2 (0.43) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26378041 | 0.78 | PPM1B (0.49) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL18073218 | 0.77 | TFPI2 (0.54) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL21851614 | 0.76 | TFPI2 (0.56) | TFPI2PPP5CPPP2CANPY4RPPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310418-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | LIXTE BIOTECHNOLOGY, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310418-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | BCL3, BCL2L10, BIRC3 | TFPI2 2757/4885PPP5C 1024/4885PPP2CA 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.